A clinical stage biotechnology company working on a rare genetic disorder is about to become a public company, and the deal behind it is worth understanding for anyone who follows how small drug developers find the money to keep going. Oak Hill Bio announced a business combination with Research Alliance Corporation III (NASDAQ: RACC), a special purpose acquisition company (SPAC) sponsored by RA Capital Management. Once the deal closes, expected by the end of 2026, the combined business will reincorporate in Delaware, take the name Oak Hill Bio Inc, and list on the Nasdaq Capital Market under the ticker OAKH.
The mechanics of the deal are worth walking through because they explain how a private biotech can suddenly find itself with real money to spend. RACC currently holds $75 million in a trust account, and RA Capital has agreed to fully backstop that amount, meaning the cash will be there regardless of how existing RACC shareholders vote. On top of that, a $100 million private financing has been arranged. Of that amount, $45 million was already funded by RA Capital through what is known as a SAFE, or simple agreement for future equity, a common early stage financing tool that lets an investor put money into a company now in exchange for shares later, once specific terms such as a future price or valuation are set. The remaining portion of the $100 million is expected to come from a group of investors buying shares at $10.00 each once the deal closes. Combined with $32.5 million Oak Hill Bio raised in an earlier funding round, the company says it will have enough cash to carry its lead drug through a Phase 3 trial and, potentially, an application for regulatory approval in the second half of 2029.
That drug is called rugonersen, and it targets Angelman syndrome, a severe neurodevelopmental condition that affects roughly 30,000 people across the United States and the five largest European economies. Patients with Angelman syndrome typically experience developmental delays, seizures, and limited speech, and there are currently no treatments that address the underlying cause of the disease rather than just its symptoms. Rugonersen works by binding to a specific piece of genetic material in the brain, with the goal of switching a silenced gene called UBE3A back on. The drug was originally developed by Roche Holding AG (SIX: RO), which licensed it to Oak Hill Bio last year, and it recently entered a pivotal Phase 3 trial after dosing its first patient in July 2026.
Leadership continuity appears to be part of the pitch to investors. Josh Distler, who currently runs Oak Hill Bio, will stay on as chief executive of the combined company, and a current RACC board member who previously served as chief financial officer of a biotech company will remain on the board after closing. Matthew Hammond, a partner at RA Capital who also leads RACC, framed the arrangement as a vote of confidence in both the science and the team executing on it.
A deal of this size involves a fairly long list of financial and legal advisors. Leerink Partners, UBS Investment Bank, Wells Fargo Securities, and LifeSci Capital are handling the private placement, while Leerink also advised RACC directly. Goodwin Procter is representing Oak Hill Bio and Cooley is representing RACC, with Kirkland and Ellis advising the placement agents.
What happens next depends largely on regulators and shareholders. RACC still needs to file a registration statement with the Securities and Exchange Commission, and RACC’s shareholders will need to approve the transaction before it can close. For patients and families watching the Angelman syndrome space, the more immediate story is simpler: a drug that has already shown promise in early trials now has a clearer, better funded path toward the finish line.
